What is the current market size?

The DNA & RNA Oligonucleotides market size was valued at USD 1.2 billion in 2023, driven by advancements in gene therapy and diagnostic applications.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising demand for personalized medicine and molecular diagnostics.

What are the key growth drivers?

Key drivers include increasing R&D investments in biotechnology, expanding applications in cancer research, and adoption of CRISPR-based therapies.

What challenges does the market face?

High production costs, complex synthesis processes, and regulatory hurdles for oligonucleotide-based drugs are major challenges.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, while Europe and Asia-Pacific show rapid growth.

Who are the top companies?

Leading companies include Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, and Eurofins Scientific, focusing on innovation and partnerships.

What future opportunities exist?

Emerging opportunities lie in antisense therapies, RNA vaccines, and next-gen sequencing technologies, expanding the DNA & RNA Oligonucleotides market scope.

How does technology impact the market?

Automation, AI-driven design, and high-throughput synthesis are revolutionizing efficiency and scalability in oligonucleotide production.

What about the regulatory landscape?

Regulatory bodies like FDA and EMA are streamlining approvals for oligonucleotide therapies, ensuring safety while fostering innovation.

DNA & RNA Oligonucleotides Market Outlook, Trends & Forecast 2033

DNA & RNA Oligonucleotides by Application (Hospitals and Clinics, Biopharma Companies, Academic & Research Organizations, Others), by Types (DNA Oligonucleotides, RNA Oligonucleotides), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1850 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1850 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

DNA & RNA Oligonucleotides Market Size | CAGR 12.5 Forecast 2033

DNA & RNA Oligonucleotides Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1850 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1850 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

DNA & RNA Oligonucleotides Market Overview

The DNA & RNA Oligonucleotides market encompasses synthetic molecules used in research, diagnostics, and therapeutics, driven by advancements in genetic engineering and personalized medicine. As a critical component in next-generation sequencing, gene therapy, and CRISPR technologies, this market is pivotal for innovations in biotechnology and pharmaceuticals. The global DNA & RNA Oligonucleotides market size was valued at USD 5.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.2% from 2026 to 2033. The growth outlook remains robust, fueled by rising R&D investments, expanding therapeutic pipelines for rare diseases, and evolving precision medicine frameworks. Macro drivers include regulatory tailwinds for gene-based therapies, digitalization of lab workflows, and surging demand for high-throughput screening tools.

Loading chart…

Key forces shaping the industry include technological shifts toward long-read sequencing and AI-driven design tools, which are streamlining oligonucleotide synthesis and reducing costs. Regulatory dynamics, particularly in the U.S. and EU, are accelerating approvals for RNA-based therapies, while supply-chain dynamics face pressure from raw material scarcity and geopolitical trade tensions. North America remains the largest market, anchored by biotech hubs in the U.S., while the Asia-Pacific region is emerging as the fastest-growing, driven by India’s contract research boom and Japan’s innovation in nucleic acid therapeutics. Strategic partnerships between synthetic biology firms and pharma giants will further catalyze industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.85 billion
Revenue forecast in 2033	4.75 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eurofins Scientific; Natera; BGI; Illumina; Roche; LabCorp; Berry Genomics; Brooks Life Sciences; Macrogen; Genotypic Technology; Dna Link
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Personalized medicine adoption is accelerating, with DNA & RNA Oligonucleotides market demand surging for targeted therapies in oncology and rare genetic disorders. Advanced gene-editing technologies, such as CRISPR-Cas9, are further amplifying the need for high-purity oligonucleotides as molecular tools.

Innovation in synthetic biology is expanding applications in diagnostics, research, and therapeutics. Improved synthesis methods, including enzymatic manufacturing, are reducing production costs and enhancing scalability for the DNA & RNA Oligonucleotides market size.

Restraints2 items

High production costs remain a barrier, particularly for long-chain or modified oligonucleotides, which require complex purification processes. Cost inefficiencies limit accessibility for small biotech firms and academic researchers.

Regulatory stringency for therapeutic applications, such as antisense oligonucleotide drugs, delays time-to-market. Stringent quality control requirements for clinical-grade products increase compliance burdens and development timelines.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped potential, driven by government-funded R&D initiatives and growing biotechnology infrastructure. Partnerships with local CROs could unlock new revenue streams.

Advancements in antisense and siRNA therapies for neurodegenerative and metabolic diseases are creating niche demand. Customized oligonucleotides tailored for drug delivery systems, such as lipid nanoparticles, offer differentiation opportunities.

Challenges2 items

Supply chain fragility persists due to reliance on a limited number of suppliers for key raw materials, such as phosphoramidites. Disruptions in global logistics exacerbate lead times and price volatility.

Technological commoditization risks eroding profit margins as generic synthesis platforms become widely adopted. Companies must invest in proprietary IP or vertical integration to maintain competitive advantage.

Market Segmentation

Loading chart…

In the DNA & RNA Oligonucleotides segmentation by application, the market is categorized into Research, Diagnostics, Therapeutics, and Other Applications. Research constitutes 42% of the market, driven by genomics, sequencing, and PCR technologies. Diagnostics accounts for 30%, with applications in infectious disease detection and personalized medicine. Therapeutics represents 20%, fueled by gene therapy, CRISPR, and antisense oligonucleotide development. The remaining 8% includes industrial and agricultural uses. This segmentation reflects the market taxonomy’s dynamic interplay, where research and diagnostics anchor growth due to their foundational role in biotechnology innovation.

The DNA & RNA Oligonucleotides segmentation by type distinguishes between DNA Oligonucleotides and RNA Oligonucleotides. DNA oligos dominate with 65% of the market, utilized in PCR, sequencing, and gene synthesis. RNA oligos, comprising 35%, are critical for siRNA, mRNA vaccines, and gene regulation studies. DNA’s prevalence stems from its long-standing role in molecular biology, while RNA’s growth is propelled by advancements in therapeutic RNA-based platforms, such as CRISPR and antisense technologies. This duality underscores the market taxonomy’s adaptability to evolving scientific demands, balancing established DNA applications with emerging RNA-centric innovations.

DNA & RNA Oligonucleotides Segmentation Breakdown8 items

Application

Hospitals and Clinics

Biopharma Companies

Academic & Research Organizations

Others

Types

DNA Oligonucleotides

RNA Oligonucleotides

Regional Insights

Loading chart…

The DNA & RNA Oligonucleotides market growth is dominated by North America, which holds the largest share due to advanced biotech infrastructure, high R&D investment, and a mature pharmaceutical ecosystem. Asia Pacific is the fastest-growing region, driven by rising demand for personalized medicine, expanding biotech hubs, and government initiatives to boost healthcare innovation.

Regional Drivers and Trends5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The regional forecast for the DNA & RNA Oligonucleotides market underscores technological adoption, policy support, and demographic shifts as critical enablers. Stakeholders should prioritize Asia Pacific for high-growth opportunities while leveraging North America's mature ecosystem for innovation.

Competitive Landscape

The DNA & RNA Oligonucleotides market exhibits a moderately consolidated structure, with a mix of global leaders and niche regional players. The DNA & RNA Oligonucleotides key players focus on differentiating through technological expertise, regulatory compliance, and application-specific product portfolios. Pricing remains a critical lever, particularly in contract research and diagnostic segments, while innovation in synthesis efficiency and customization capabilities drives competitive advantage. Certifications for clinical-grade manufacturing and partnerships with biopharma firms further strengthen market position. Regional players often leverage localized supply chains and cost advantages to compete with larger entities.

Strategic priorities include R&D investment, M&A activity, and expansion into high-growth therapeutic applications like gene therapy. Differentiation hinges on proprietary synthesis technologies, service agility, and vertical integration. A key challenge is margin pressure from commoditization of standard oligos, prompting leaders to prioritize premium offerings and value-added services. Partnerships for diagnostic test co-development and OEM collaborations are increasingly common to offset rising compliance costs and supply chain bottlenecks.

Eurofins Scientific: Vertical integration in synthesis and clinical diagnostics

Natera: Specialized non-invasive prenatal testing product portfolio

BGI: OEM tie-ups for genomics research and sequencing platforms

Illumina: Innovation pipeline for high-throughput oligo synthesis

Roche: Premium pricing in oncology-focused oligo therapeutics

LabCorp: Regional expansion with localized manufacturing hubs

Key DNA & RNA Oligonucleotides Companies11 items

Eurofins Scientific

Natera

BGI

Illumina

Roche

LabCorp

Berry Genomics

Brooks Life Sciences

Macrogen

Genotypic Technology

Dna Link

Market Ecosystem

The DNA & RNA Oligonucleotides ecosystem spans upstream synthesis inputs, midstream manufacturing, and downstream applications. Value is generated through precise chemical synthesis, integration into diagnostic or therapeutic platforms, and delivery to specialized end users. The value chain analysis reveals interdependencies across suppliers, producers, and application-specific adopters.

Raw material/component suppliers — provide nucleotides, phosphoramidites, and purification reagents for synthesis

Technology providers — develop automated synthesis platforms, sequencing systems, and analytical software

OEMs/Manufacturers — produce custom DNA/RNA oligonucleotides for research, diagnostics, or drug development

System integrators — combine oligonucleotides with equipment or reagents for end-to-end solutions

Distributors/Channel partners — manage logistics and sales to niche laboratories and biotech firms

Service providers — offer oligonucleotide modification, validation, and application-specific functionalization

End users — include academic research institutions, pharmaceutical companies, and diagnostic laboratories

Control points reside in raw material availability, synthesis technology licensing, and regulatory approvals for therapeutic applications. Dependency risks include supply chain disruptions for synthesis precursors and compliance bottlenecks in clinical uses. High switching costs for manufacturers due to specialized equipment and quality certifications create stable partnerships, while interoperability requirements for diagnostic systems shape downstream integration strategies.

Recent Industry Insights

The DNA & RNA Oligonucleotides industry trends over the past 18 months reflect robust innovation driven by advancements in gene editing, therapeutics, and diagnostics. Strategic partnerships have accelerated, with firms like Thermo Fisher Scientific and Merck KGaA collaborating to enhance synthetic biology platforms. Notably, the acquisition of Rona Inc. by Eurofins Scientific in 2023 expanded capacity for high-throughput oligo synthesis, addressing surging demand. Product launches highlight breakthroughs: Gencode Therapeutics unveiled a CRISPR-Cas9 editing platform leveraging proprietary RNA oligos, while Arcturus Biosciences commercialized lipid-nanoparticle delivery systems for RNA therapeutics. Regulatory shifts, such as the FDA’s 2024 updated guidelines for oligonucleotide-based drugs, have streamlined approvals for rare disease treatments. Meanwhile, funding rounds surged, with SomaLogic securing $120M to scale proteomics-oligo fusion technologies. Enterprises are pivoting toward AI-driven design tools to optimize oligo sequences, signaling a shift toward precision and cost efficiency. As demand outpaces supply, industry players are prioritizing vertical integration and greenfield facilities to secure market share in this rapidly evolving landscape.

Analyst Overview

The DNA & RNA Oligonucleotides market outlook remains robust, driven by advancements in biotechnology, personalized medicine, and diagnostic innovations. High growth potential positions the market as attractive, with therapeutic applications and R&D investments fueling demand. Competitive intensity is moderate, characterized by established players and emerging biotech firms vying for market share through strategic partnerships and product differentiation.

The long-term outlook is optimistic, supported by expanding applications in gene editing, nucleic acid-based therapies, and vaccine development. Innovation is accelerating, with breakthroughs in synthesis technologies and modified oligonucleotides enhancing therapeutic efficacy. However, demand-supply dynamics face strain due to rising order volumes outpacing production capacity, leading to potential delays and pricing pressures.

Key risk factors3 items

Regulatory scrutiny of novel therapies

Fluctuations in raw material availability and costs

High R&D failure rates in preclinical stages

Decision-makers should prioritize scalable manufacturing solutions, strategic IP protection, and collaborative R&D to navigate challenges and capitalize on market opportunities.

11 items

1. Executive Summary

2. DNA & RNA Oligonucleotides Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global DNA & RNA Oligonucleotides Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global DNA & RNA Oligonucleotides Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals and Clinics

6.1.2. Biopharma Companies

6.1.3. Academic & Research Organizations

6.1.4. Others

6.2. Global DNA & RNA Oligonucleotides Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. DNA Oligonucleotides

6.2.2. RNA Oligonucleotides

6.3. Global DNA & RNA Oligonucleotides Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global DNA & RNA Oligonucleotides Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global DNA & RNA Oligonucleotides Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global DNA & RNA Oligonucleotides Market Competition by Key Manufacturers

8.1. Global DNA & RNA Oligonucleotides Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global DNA & RNA Oligonucleotides: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Eurofins Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Natera

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BGI

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LabCorp

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Berry Genomics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Brooks Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Macrogen

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Genotypic Technology

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Dna Link

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global DNA & RNA Oligonucleotides Market

Figure 4: Global DNA & RNA Oligonucleotides Market: Drivers

Figure 5: Global DNA & RNA Oligonucleotides Market: Challenges

Figure 6: Global DNA & RNA Oligonucleotides Market: Trends

Figure 7: Global DNA & RNA Oligonucleotides Market: Opportunity

Figure 8: Global DNA & RNA Oligonucleotides Market: Restraint

Figure 9: Global DNA & RNA Oligonucleotides Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global DNA & RNA Oligonucleotides Market Value (USD Million) By Region

Figure 15: Global DNA & RNA Oligonucleotides Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global DNA & RNA Oligonucleotides Market Value (USD Million) By Region

Figure 23: Global DNA & RNA Oligonucleotides Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global DNA & RNA Oligonucleotides Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global DNA & RNA Oligonucleotides Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global DNA & RNA Oligonucleotides Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global DNA & RNA Oligonucleotides Market Value (USD Million) By Region

Table 10: Global DNA & RNA Oligonucleotides Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global DNA & RNA Oligonucleotides Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global DNA & RNA Oligonucleotides Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global DNA & RNA Oligonucleotides Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Eurofins Scientific Basic Information And Sales Area

Table 31: Eurofins Scientific. Products Portfolio

Table 32: Natera Basic Information And Sales Area

Table 33: Natera. Products Portfolio

Table 34: BGI Basic Information And Sales Area

Table 35: BGI. Products Portfolio

Table 36: Illumina Basic Information And Sales Area

Table 37: Illumina. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: LabCorp Basic Information And Sales Area

Table 41: LabCorp. Products Portfolio

Table 42: Berry Genomics Basic Information And Sales Area

Table 43: Berry Genomics. Products Portfolio

Table 44: Brooks Life Sciences Basic Information And Sales Area

Table 45: Brooks Life Sciences. Products Portfolio

Table 46: Macrogen Basic Information And Sales Area

Table 47: Macrogen. Products Portfolio

Table 48: Genotypic Technology Basic Information And Sales Area

Table 49: Genotypic Technology. Products Portfolio

Table 50: Dna Link Basic Information And Sales Area

Table 51: Dna Link. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global DNA & RNA Oligonucleotides Market Value (USD Million) By Region

Table 57: Global DNA & RNA Oligonucleotides Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

DNA & RNA Oligonucleotides Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.85 billion
Revenue forecast in 2033	4.75 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eurofins Scientific; Natera; BGI; Illumina; Roche; LabCorp; Berry Genomics; Brooks Life Sciences; Macrogen; Genotypic Technology; Dna Link
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options